Další formáty:
BibTeX
LaTeX
RIS
@inproceedings{746164, author = {Grell, Peter and Petráková, Katarína and Šimíčková, Marta and Svoboda, Marek and Nekulová, Miloslava and Pecen, Ladislav and Vyzula, Rostislav and Nenutil, Rudolf}, address = {Budapešť}, booktitle = {19th meeting of European Association For Cancer Research}, edition = {1.}, keywords = {serum her2/neu;trastuzumab;breast cancer}, language = {eng}, location = {Budapešť}, pages = {207-207}, publisher = {European Association for Cancer Research}, title = {Serum HER-2/neu: a tumor marker for monitoring response to treatment of metastatic breast cancer with trastuzumab}, year = {2006} }
TY - JOUR ID - 746164 AU - Grell, Peter - Petráková, Katarína - Šimíčková, Marta - Svoboda, Marek - Nekulová, Miloslava - Pecen, Ladislav - Vyzula, Rostislav - Nenutil, Rudolf PY - 2006 TI - Serum HER-2/neu: a tumor marker for monitoring response to treatment of metastatic breast cancer with trastuzumab PB - European Association for Cancer Research CY - Budapešť KW - serum her2/neu;trastuzumab;breast cancer N2 - Introduction: HER-2/neu, the oncoprotein from growth factor receptor family, is overexpressed in primary tumor tissue in approximately 30% patients with breast cancer. Extracellular domain of this oncoprotein is released into the circulation and by recent studies it has prognostic and predictive signification similar to HER-2/neu in tissue. Material and Methods: We evaluated dynamics of serum HER-2/neu (S_HER2) changes during the course of trastuzumab-based therapy, by the specific antibody directed against the extracellular domain (ELISA, Oncogene Science, USA). We had opportunity to repeatedly tested S_HER2 in 69 patients with metastatic breast cancer undergoing treatment in years 200-2005 in our institute. Results: Patients without the response to treatment at the time of the first restaging (3 months), had significantly elevated S_HER2 levels, that generally do not drop below the discriminatory level. The patients with the best clinical response achieved (complete or partial response) are commonly S_HER2 negative after 3 months of the therapy, even if they were serum-positive at the beginning of the treatment. Serum CA15-3 and CEA levels do not show significant differences in this two groups of responders. Likewise in longitudinally monitoring over the time course of trastuzumab-based treatment the predictor of the therapy failure is mainly elevated S_HER2. Conclusion: Monitoring the concentrations of serum HER2 during the trastuzumab therapy appears to be a suitable therapy efficacy validation parameter both at the start and during long-term therapy application. Acknowledgements: The work was supported by grants from IGA MZCR: No. NR/8335-3 and No. NR/8270-3. ER -
GRELL, Peter, Katarína PETRÁKOVÁ, Marta ŠIMÍČKOVÁ, Marek SVOBODA, Miloslava NEKULOVÁ, Ladislav PECEN, Rostislav VYZULA a Rudolf NENUTIL. Serum HER-2/neu: a tumor marker for monitoring response to treatment of metastatic breast cancer with trastuzumab. In \textit{19th meeting of European Association For Cancer Research}. 1. vyd. Budapešť: European Association for Cancer Research, 2006, s.~207-207.
|